Fig. 4: Kaplan–Meier curve of progression-free survival and overall survival in the SAGC group with different initial dose of anlotinib. | Nature Communications

Fig. 4: Kaplan–Meier curve of progression-free survival and overall survival in the SAGC group with different initial dose of anlotinib.

From: Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial

Fig. 4: Kaplan–Meier curve of progression-free survival and overall survival in the SAGC group with different initial dose of anlotinib.The alternative text for this image may have been generated using AI.

A Progression-free survival. B Overall survival. Note: p values are two-sided and are based on log-rank test. Abbreviations: CI confidence interval, HR hazard ratio, NA not available.

Back to article page